- Joined
- Jun 30, 2015
- Messages
- 1,596
In what possibly looks like a way to shoehorn an LSD trip into an insurance billable time slot (or perhaps provide a backup for a session that's gone iff the rails,) MindMed says it has filed a patent application for, “a neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session.”
I'm curious as to what it is. Current bets are on ketanserin as opposed to benzodiazepines, quetiapine, trazodone, mirtazapine, or varied antipsychotics. I'm not sure how they are going to patent it, though, since it's in the public domain. I guess we'd have to look at the patent application to see if it's a novel delivery method or something. The question I have is how an antagonist could kill an LSD trip. A phenethylamine or 4-substituted tryptamine, sure, but LSD's structure locks it into the receptor.
Anybody try aborting a trip with ketanserin?
I'm curious as to what it is. Current bets are on ketanserin as opposed to benzodiazepines, quetiapine, trazodone, mirtazapine, or varied antipsychotics. I'm not sure how they are going to patent it, though, since it's in the public domain. I guess we'd have to look at the patent application to see if it's a novel delivery method or something. The question I have is how an antagonist could kill an LSD trip. A phenethylamine or 4-substituted tryptamine, sure, but LSD's structure locks it into the receptor.
Anybody try aborting a trip with ketanserin?
MindMed Acquires Exclusive License to Eight Clinical Trials of LSD, Partners with World-Leading Psychedelic Research Laboratory at University Hospital Basel - MindMed
Multi-year deal gives MindMed access to largest collection of clinical trials & knowhow for LSD psychedelic research including a Phase 2 clinical trial of LSD for the treatment of anxiety Basel, Switzerland (April 1, 2020): Mind Medicine (MindMed) Inc. (NEO: MMED OTC: MMEDF), the leading...
www.mindmed.co